132 related articles for article (PubMed ID: 37952139)
41. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
42. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
[TBL] [Abstract][Full Text] [Related]
43. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis.
Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Gouill SL; Béné MC; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):861.e1-861.e7. PubMed ID: 34245928
[TBL] [Abstract][Full Text] [Related]
44. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft.
Little JS; Duléry R; Shapiro RM; Aleissa MM; Prockop SE; Koreth J; Ritz J; Antin JH; Cutler C; Nikiforow S; Romee R; Issa NC; Ho VT; Baden LR; Soiffer RJ; Gooptu M
Transplant Cell Ther; 2024 Feb; 30(2):233.e1-233.e14. PubMed ID: 37984797
[TBL] [Abstract][Full Text] [Related]
45. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
46. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
[TBL] [Abstract][Full Text] [Related]
47. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang S; Penack O; Terzer T; Schult D; Majer-Lauterbach J; Radujkovic A; Blau IW; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Haematologica; 2021 Feb; 106(2):446-453. PubMed ID: 31974195
[TBL] [Abstract][Full Text] [Related]
48. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia.
Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M
Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507
[TBL] [Abstract][Full Text] [Related]
49. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.
Nagler A; Kanate AS; Labopin M; Ciceri F; Angelucci E; Koc Y; Gülbas Z; Arcese W; Tischer J; Pioltelli P; Ozdogu H; Afanasyev B; Wu D; Arat M; Peric Z; Giebel S; Savani B; Mohty M
Haematologica; 2021 Jun; 106(6):1591-1598. PubMed ID: 32354866
[TBL] [Abstract][Full Text] [Related]
50. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Oran B; Garcia-Manero G; Saliba RM; Alfayez M; Al-Atrash G; Ciurea SO; Jabbour EJ; Mehta RS; Popat UR; Ravandi F; Alousi AM; Kadia TM; Konopleva M; DiNardo CD; Rezvani K; Shpall EJ; Sharma P; Kantarjian HM; Champlin RE; Daver N
Cancer; 2020 May; 126(10):2193-2205. PubMed ID: 32125707
[TBL] [Abstract][Full Text] [Related]
51. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
52. Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes.
Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ; Jurdi NE
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38734182
[TBL] [Abstract][Full Text] [Related]
53. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
Mulroney CM; Abid MB; Bashey A; Chemaly RF; Ciurea SO; Chen M; Dandoy CE; Diaz Perez MA; Friend BD; Fuchs E; Ganguly S; Goldsmith SR; Kanakry CG; Kim S; Komanduri KV; Krem MM; Lazarus HM; Ljungman P; Maziarz R; Nishihori T; Patel SS; Perales MA; Romee R; Singh AK; Reid Wingard J; Yared J; Riches M; Taplitz R
Br J Haematol; 2021 Jul; 194(1):145-157. PubMed ID: 34124796
[TBL] [Abstract][Full Text] [Related]
54. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
[TBL] [Abstract][Full Text] [Related]
55. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
[TBL] [Abstract][Full Text] [Related]
56. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
Paviglianiti A; Ngoya M; Peña M; Boumendil A; Gülbas Z; Ciceri F; Bonifazi F; Russo D; Fegueux N; Stolzel F; Bulabois CE; Socié G; Forcade E; Solano C; Finel H; Robinson S; Glass B; Montoto S
Bone Marrow Transplant; 2024 May; 59(5):597-603. PubMed ID: 38331980
[TBL] [Abstract][Full Text] [Related]
57. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
58. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy.
Nieto JC; Roldán E; Jiménez I; Fox L; Carabia J; Ortí G; Puigdefàbregas L; Gallur L; Iacoboni G; Raheja P; Pérez A; Bobillo S; Salamero O; Palacio C; Valcárcel D; Crespo M; Bosch F; Barba P
Leukemia; 2020 Dec; 34(12):3420-3425. PubMed ID: 32393842
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
60. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
